

Role of *Helicobacter pylori* in Damaging the Gastroduodenal Mucosa

Marcellus Simadibrata

Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta

Helicobacter pylori is a gram negative helix-shaped bacteria which is pathogen and can live in the stomach, between the mucus and the epithelial mucosa.¹ *Helicobacter pylori* can damage the Gastroduodenal mucosa, causing inflammation, ulceration, MALT lymphoma and cancer. It was identified in 1982 by Australian scientists Barry Marshall and Robin Warren, and in 1994, the International Agency for Research on Cancer classified *Helicobacter pylori* as a carcinogen, or cancer-causing agent, in humans.²

Virulence factors of *Helicobacter pylori*, include Cag A, Vac A, Bab A etc, induce proinflammatory cytokine production and release, proliferative epithelial cells signaling, and epithelial damage.^{3,4} There are two possible mechanisms currently being investigated by which *Helicobacter pylori* could cause cancer. The first mechanism involves the production of free radicals near *Helicobacter pylori* as well as an increased rate of host cell mutation. The second mechanism involves enhancement of the transformed host cell phenotype by altering cell proteins such as adhesion proteins. So *Helicobacter pylori* causes inflammation and locally high levels of TNF- α and/or interleukin 6.^{5,6}

The inflammatory changes on gastroduodenal mucosa caused by *Helicobacter pylori* infection can be seen macroscopically by endoscopy examination and microscopically by histopathology examination.^{7,8} Tissue damage due to free radicals can be examined by measuring the malondialdehyde compound.^{9,10}

Laura Dairi et al in their study reported that from 20 patients with *Helicobacter pylori* (+), the average level of malondialdehyde was 1.58 $\mu\text{mol/mL}$ while in 20 other patients with *Helicobacter pylori* (-), the malondialdehyde level was 1.19 $\mu\text{mol/mL}$ with p value 0.013. They concluded that the mean serum levels of malondialdehyde was higher in *Helicobacter pylori* positive gastritis than *Helicobacter pylori* negative.¹¹

We have some consensus and guidelines for the *Helicobacter pylori* eradication therapy using triple or quadruple drug regimens.¹² Some experts suggest that rebamipide can prevent *Helicobacter pylori*

infection, reduce inflammation, accelerate healing after eradication, promote ulcer healing, and prevent progression of preneoplastic lesions.¹³

REFERENCES

1. *Helicobacter pylori* - Chapter 3 - 2016 Yellow Book | Travelers' Health CDC [serial online] [cited 2017 April 25] Available from: URL: <http://wwwnc.cdc.gov>.
2. NIH National Cancer Institute. *Helicobacter pylori* and Cancer [serial online] [cited 2018 May 09]. Available from: URL: <https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/h-pylori-fact-sheet>.
3. Atherton JC. The pathogenesis of *Helicobacter pylori*-induced gastro-duodenal diseases. Annual Rev Pathol: Mechanisms of Disease 2006;1:63-96.
4. MicrobeWiki. Gastritis and peptic ulcer disease caused by *Helicobacter pylori* [serial online] [cited 2018 May 8]. Available from: URL: https://microbewiki.kenyon.edu/index.php/Gastritis_and_Peptic_Ulcer_Disease_Caused_by_Helicobacter_pylori.
5. Tsuji S, Kawai N, Tsujii M, Kawano S, Hori M. Review article: inflammation-related promotion of gastrointestinal carcinogenesis--a perigenetic pathway. Aliment Pharmacol Ther 2003;18:82-9.
6. Suganuma M, Yamaguchi K, Ono Y. TNF- α -inducing protein, a carcinogenic factor secreted from *H. pylori*, enters gastric cancer cells. Int J Cancer 2008;123:117-22.
7. Rajeswari P, Visalakshi P, Arbind KP. Clinical, endoscopic and histopathological study of *Helicobacter pylori* related gastritis in adults Tertiary Care Teaching Hospital. Intern J Scienc Study 2017;5:5-10.
8. Dwivedi M, Misra SP, Misra V. Nodular gastritis in adults: Clinical features, endoscopic appearance, histopathological features, and response to therapy. J Gastroenterol Hepatol 2008;23:943-7.
9. Simadibrata M, Syam AF, Rani A, Wanandi SI, Fauzi A, Abdullah M. Anti free radical & anti inflammatory effect of rebamipide in chronic gastritis. Open J Gastroenterol 2013;3: 72-7.
10. Everett SM, Singh R, Leuratti C, White KLM, Neville P, Greenwood D, et al. Levels of Malondialdehyde-Deoxyguanosine in the gastric mucosa - relationship with lipid peroxidation, Ascorbic Acid, and *Helicobacter pylori*. Cancer Epidemiology, Biomarkers & Prevention 2001;10:369-76.
11. Dairi L, Siregar GA, Sungkar T. The Comparison of Serum Malondialdehyde level between *H. Pylori* positive and *H. Pylori* negative gastritis patients. Indones J Gastroenterol Hepatol Dig Endosc 2018;19:3-6.

12. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. The European *Helicobacter* Study Group (EHSG). Management of *Helicobacter pylori* infection-the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-64.
13. Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 2003;18:8-13.